All In Biotech

Drug Trial Radar · NCT06502379

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD8965 Following Single and Multiple Ascending Dose Administration to Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Aug 2, 2024

Primary completion

Jun 1, 2025

Study completion Nov 15, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.

Conditions

  • Healthy Participants

Interventions

  • AZD8965Drug

    AZD8965 will be administered orally.

  • PlaceboOther

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 3A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: SAEs: From Screening (Day -28) to 5 weeks; AEs: From Day 1 to 5 weeks
  2. Parts 2 and 3B: Number of participants with AEs and SAEsTime frame: SAEs: From Screening (Day -28) to 8 weeks; AEs: From Day 1 to 8 weeks.
  3. Part 4: Maximum observed drug concentration (Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  4. Part 4: Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  5. Part 4: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  6. Part 4: Time to reach maximum observed concentration (tmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  7. Part 4: Partial area under the concentration-time curve from time t1 to time t2 [AUC(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  8. Part 4: Terminal elimination half-life (t½λz)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  9. Part 4: Mean Residence Time (MRTinf)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  10. Part 4: Apparent total body clearance (CL/F)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  11. Part 4: Apparent volume of distribution based on the terminal (Vz/F)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  12. Part 4: Accumulation ratio for AUC (Rac AUC)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  13. Part 4: Accumulation ratio for Cmax (Rac Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  14. Part 4: Individual and cumulative amount of unchanged drug excreted into urine from time t1 to time t2 [Ae(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 5
  15. Part 4: Individual and cumulative percentage of dose excreted unchanged in urine from time t1 to time t2 [fe(t1-t2)]Time frame: From Day 1 (pre-dose) to Day 5
  16. Part 4: Relative bioavailability calculated as test AUC/reference AUC (Frel AUC)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  17. Part 4: Relative bioavailability calculated as test Cmax/reference Cmax (Frel Cmax)Time frame: From Day 1 (pre-dose) to Day 7 (72-hour post dose)
  18. Part 4: Renal clearance (CLR)Time frame: From Day 1 (pre-dose) to Day 5

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.